Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
LONDON, March 26, 2012/PRNewswire-FirstCall/ --
Results presented from new VOYAGER sub-analysis
This release is INTENDED EXCLUSIVELY FOR EUROPEAN media
AstraZeneca today announced the results of a sub-analysis from the
VOYAGER individual patient data meta-analysis, which suggests that
achieving an LDL-C goal of <70 mg/dL or >50% reduction in
LDL-C levels in patients at high risk requires aggressive statin
therapy. These goals reflect the latest European Society of
Cardiology (ESC) and European Atherosclerosis Society (EAS)
Guidelines for the Management of Dyslipidaemias. Results showed
that a significantly greater percentage of patients achieved this
goal with CRESTOR(TM) (rosuvastatin) than with equal or double
doses of atorvastatin (Lipitor(R)) or simvastatin. These findings
were presented at the 2012 International Symposium on
Atherosclerosis in Sydney, Australia.
This sub-analysis was designed to determine the percentage of
high-risk patients treated with rosuvastatin 10-40 mg, atorvastatin
10-80 mg or simvastatin 10-80 mg who achieved this recommended
LDL-C goal. Additional findings from the VOYAGER sub-analysis
included:
- As statin dose increased, a higher percentage of patients
achieved LDL-C
<70 mg/dL or >50% LDL-C reduction.
- Statistically significant differences (all p<0.001)were
observed across a
range of statin therapy comparisons, including:
- Rosuvastatin 10mg vs atorvastatin 10-20mg and simvastatin
10-20mg
- Rosuvastatin 20mg vs atorvastatin 20-40mg and simvastatin
20-80mg
- Rosuvastatin 40mg vs atorvastatin 40-80mg and simvastatin
40-80mg
Percentage of high-risk patients achieving LDL-C goal
(Photo: http://www.newscom.com/cgi-bin/prnh/20120326/521032 )
"These data reinforce CRESTOR as an important medication that helps get high-risk patients to recommended treatment targets" said Russ Esterline, VP Global Product Development Cardiovascular, AstraZeneca. "Additionally, these favourable results add to the wealth of data that demonstrate CRESTOR is well positioned in the market to remain a statin of choice for physicians treating patients at increased-risk."
Guidelines continue to stress the importance of achieving
aggressive LDL-C treatment goals in higher risk patients and the
important role of statins in achieving these goals. Under the
recently updated ESC/EAS guidelines, target LDL-C goals have become
more stringent, particularly for patients with established
cardiovascular disease, type II diabetes and for other patients
classified as being at very high risk of a primary or secondary
cardiovascular event.The ESC/EAS guidelines recommend that
clinicians should aim for LDL-C levels below <3.0 mmol/L (~115
mg/dL) in moderate risk patients, <2.5 mmol/L (~100 mg/dL) in
high-risk patients and <1.8 mmol/L (~70 mg/dL) and/or at least
50 percent reduction in levels if this target cannot be reached in
very high-risk patients.
CRESTOR has been researched extensively for over 13 years,
including 120 clinical trials of more than 67,000 patients
worldwide from more than 55 countries.
NOTES TO EDITORS
VOYAGER (An indiVidual patient data meta-analysis Of statin therapY
in At risk Groups: Effects of Rosuvastatin, atorvastatin and
simvastatin) is a unique individual patient data meta-analysis of
32 258 patients from 37 randomised studies comparing the lipid
modifying effects of rosuvastatin with that of atorvastatin and
simvastatin. The patients include almost 9,000 with diabetes and
over 15,000 with atherosclerotic disease.
CRESTOR has now received regulatory approvals in over 109
countries. Worldwide, doctors have written nearly 330 million
prescriptions for CRESTOR.Data from clinical trials and real world
use shows that the safety profile for rosuvastatin is in line with
that of other marketed statins.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical
business with a primary focus on the discovery, development and
commercialisation of prescription medicines for gastrointestinal,
cardiovascular, neuroscience, respiratory and inflammation,
oncology and infectious disease. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide. For more information please visit:
http://www.astrazeneca.com
Photo: http://www.newscom.com/cgi-bin/prnh/20120326/521032
Source: AstraZeneca
For further information please contact: David Ginivan, Global
Communications Director, AstraZeneca, Telephone: +44(0)1625-516973,
Mobile: +44(0)7775-412-619, david.ginivan@astrazeneca.com.
Posted: March 2012
